Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2025-03-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司2025年第一次临时股东大会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, agenda, and voting results of the 2025 first extraordinary general meeting (临时股东大会) of Zhejiang Tailin Biotechnology Co., Ltd. It details the legal compliance of the meeting process and the validity of the voting results. The document is not a financial report, earnings release, or management discussion, but a legal opinion on the shareholder meeting. This type of document is typically classified as a Regulatory Filing (RNS) because it is a legal compliance document related to corporate governance and shareholder meetings, but does not fit into more specific categories like AGM Information (which would be presentations/materials) or Declaration of Voting Results (which would be just voting results without legal opinion). The document is about the legal opinion on the shareholder meeting and its voting results, so RNS is the best fit.
2025-03-27 Chinese
关于取得专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the acquisition of 8 patent certificates by the company and its subsidiaries. It includes details about the patents but does not contain financial data, management changes, voting results, or any regulatory filings related to financial performance or governance. The document is an announcement of a corporate event (patent acquisition) rather than a financial report or regulatory filing. It is also short (1013 characters) and does not indicate it is a report or presentation. Therefore, it fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2025-03-27 Chinese
关于设立全资子公司暨取得营业执照的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhejiang Tailin Biotechnology Co., Ltd. about the establishment of a wholly-owned subsidiary and the acquisition of its business license. It includes details about the new subsidiary, its registration, purpose, and impact on the company. The document is relatively short (1476 characters) and does not contain financial statements or detailed financial data. It is a corporate announcement about a capital structure change (setting up a subsidiary with registered capital). This fits best under the category of Capital/Financing Update (CAP), as it relates to company financing activities and capital structure changes. It is not an annual report, audit report, or other financial report, nor is it a regulatory filing or report publication announcement. Therefore, the classification is CAP with high confidence.
2025-03-26 Chinese
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司2025年员工持股计划之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 employee stock ownership plan of Zhejiang Tailin Biotechnology Co., Ltd. It extensively discusses the legal compliance, procedures, and regulatory framework related to the employee stock ownership plan. The document is not a financial report, earnings release, or management discussion. It is a standalone legal opinion related to a specific corporate action (employee stock ownership plan). This fits the category of Audit Report / Information (AR), which includes applied accounting principles and legal/regulatory compliance reports related to corporate actions, excluding full annual reports. The document is over 10,000 characters, so it is not a mere announcement or certification. Therefore, the best classification is AR with high confidence. FY 2025
2025-03-24 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the company's first repurchase of its own shares. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document is short (1382 characters) and focuses on the share buyback event, not on financial results or broader company performance. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares.
2025-03-21 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is titled as a "回购报告书" which translates to a "Repurchase Report" or "Buyback Report". It details the company's plan to repurchase its own shares, including the purpose, conditions, price range, quantity, funding sources, implementation period, and risk factors. It also includes information about the board's authorization and disclosures related to the repurchase. The document is comprehensive and contains substantive details about the share repurchase plan, not just an announcement or a brief summary. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length (7866 characters) and detailed content confirm it is the report itself, not merely an announcement or certification. Therefore, the correct classification is POS with high confidence.
2025-03-14 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.